Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

By sjmartinez • October 30, 2023

Kudo M, Finn RS, Cheng AL, Zhu AX, Ducreux M, Galle PR, Sakamoto N, Kato N, Nakano M, Jia J, Vogel A. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study. Liver Cancer. 2023 Mar 4;12(5):479-493. doi: 10.1159/000529996. PMID: 37901766; PMCID: PMC10601852.

Tags: Albumin-bilirubin grade, Atezolizumab, Bevacizumab, Hematology/Oncology, Publications, Unresectable hepatocellular carcinoma

Related Posts

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study

Muffly L, Frey NV, Roloff GW, Park JH, Dholaria B, Advani AS, Bachanova V, Cassaday RD, Daunov M, Dykes KC, Irizarry Gatell V, Grunwald MR,[...]

Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer

Rodon J, O'Neil B, Lim C, Ammakkanavar NR, Torrado C, Matsuoka K, Hirai H, Miura A, Anderson B, Jin L, Hangai N, Long A, Wacheck[...]

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma

Galsky MD, Drakaki A, Basu A, McGregor B, Bedke J, Loriot Y, Kikuchi E, Guo J, Garmezy B, Sridhar SS, Singh P, Koshkin VS, Fleming[...]